The Boundaries: Innovation, Private Injury, and What the Record Cannot Prove
The remaining question in CareFirst v. Amgen is not whether antitrust law should override patents. It is how to scrutinize a competition-sensitive acquisition without treating ordinary licensing, innovation, or legitimate government petitioning as suspect. The Federal Trade Commission’s position is narrower than a rule against patent ownership: focus on the competitive setting, the exclusivity transferred, and the evidence of effect. That boundary also requires separating an antitrust violation from private injury, patent validity, and the unresolved result of the appeal.
Why the theory does not condemn ordinary licensing
The FTC begins from a concession that matters. Most patent acquisitions and licensing arrangements simply transfer rights from one party to another without changing overall competitive conditions. A license can allow an inventor to find a commercial partner. A non-exclusive license can let more than one firm use a technology or leave a rights holder free to work with a potential competitor. In ordinary circumstances, those arrangements can support commercialization rather than suppress it.
That baseline describes an important part of the CareFirst chronology. Immunex initially obtained a non-exclusive license from Roche. The FTC’s account says the license allowed Immunex to sell Enbrel without infringing Roche’s rights, while Roche retained the ability to commercialize its own version or license the rights to another company seeking to develop a competing version. The existence of a patent-related license did not itself remove every route to competition. The alleged competitive change came later, when Amgen restructured the relationship and obtained exclusive control over the patent family and two pending applications.
The relevant comparison is therefore not “patents versus no patents.” It is between a transfer that enables use and a transfer that may remove a rival’s access to an important technological input. The FTC says exclusive licenses deserve closer attention when the parties are actual or potential competitors, when a dominant firm acquires substitute rights, or when the rights cover the same product in which the acquirer already has market power. Exclusivity is a factual feature that can matter; it is not a conclusion that the deal is unlawful.
The distinction between an innovator and a dominant incumbent helps explain the innovation objection. In the example the FTC draws from Supreme Court authority, an inventor’s license to a non-competitor can enable commercialization and competition. The concern is different when a dominant firm acquires exclusive rights from an external holder whose technology could support a competing product. In the first setting, the transaction may make an invention available. In the second, it may prevent a potential rival from obtaining a substitute technology or may give the dominant firm a larger portfolio of rights that limits entry.
Applied to Amgen, the question is not whether exclusive control was commercially useful. It plainly could be useful to the buyer. The question is whether that usefulness represented competition on the merits or a way to maintain existing monopoly power through the removal of a competing route.